Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States.
Gut Microbes. 2021 Jan-Dec;13(1):1-13. doi: 10.1080/19490976.2021.1900994.
Human noroviruses are the most common viral cause of acute gastroenteritis worldwide. Currently, there are no approved vaccines or specific therapeutics to treat the disease. Some obstacles delaying the development of a norovirus vaccine are: (i) the extreme diversity presented by noroviruses; (ii) our incomplete understanding of immunity to noroviruses; and (iii) the lack of a robust cell culture system or animal model for human noroviruses. Recent advances in cultivation of norovirus, novel approaches applied to viral genomics and immunity, and completion of vaccine trials and birth cohort studies have provided new information toward a better understanding of norovirus immunity. Here, we will discuss the complex relationship between norovirus diversity and correlates of protection for human noroviruses, and how this information could be used to guide the development of cross-protective vaccines.
人类诺如病毒是全球范围内引起急性胃肠炎的最常见病毒。目前,尚无针对该疾病的批准疫苗或特定疗法。一些阻碍诺如病毒疫苗研发的障碍包括:(i)诺如病毒的极端多样性;(ii)我们对诺如病毒免疫的理解不完整;以及(iii)缺乏用于人类诺如病毒的稳健细胞培养系统或动物模型。最近在诺如病毒培养方面的进展、应用于病毒基因组学和免疫的新方法,以及疫苗试验和出生队列研究的完成,为更好地了解诺如病毒免疫提供了新信息。在这里,我们将讨论诺如病毒多样性与人类诺如病毒保护相关性之间的复杂关系,以及如何利用这些信息来指导交叉保护疫苗的开发。